Endo Pharmaceuticals’ on-again, off-again lawsuit, aimed at keeping the FDA from giving bulk compounders the ability to compete with one of it key drugs, is off again. More: Endo presses pause on litigation after FDA assurance to sort out compounding competition
read moreMore than a decade before Gilead’s patents expire for blockbuster hepatitis C drugs Epclusa and Harvoni, the company is launching authorized generics at one-third the list price—or less. But the company might actually boost sales in the process. More: With
read moreDespite being one of the lowest-paid pharma CEOs, Pascal Soriot says defeating a Pfizer takeover was right for AstraZeneca. More: AstraZeneca CEO Pascal Soriot bemoans being one of the 'lowest-paid' CEOs in pharma Source: fierce
read moreAlexion has already seen major success expanding flagship Soliris into multiple indications. And it may just have another nod on the horizon, thanks to a study showing it slashed relapse risk in a rare eye disease. More: Alexion eyes 0M-plus
read moreCall it a promise kept. For years, Amarin has staunchly defended its heart drug Vascepa, despite detractors’ disbelief that the drug truly cut cardiovascular risks. According to a new study, it does—and in a big way. More: Believe it: Just
read moreNovartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness. More: Novartis to file Lucentis for rare sight condition in premature babies Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals